The buyout is a bet by Lilly on an increasingly popular drug target known as NLRP3 inflammasomes, which are implicated in an ...

Hosts have evolved strategies to detect and respond rapidly to invading microorganisms and host-cell damage or 'danger signals'. The caspase-1 inflammasome is a dynamic complex in which specific ...

NEWTON, Mass., November 13, 2025--(BUSINESS WIRE)--Inflammasome Therapeutics (https://www.inflam.com), a clinical-stage biotech company developing a new class of drugs, Kamuvudines, for ophthalmic and ...

The potential to target the inflammasome as a therapeutic for many diseases is huge, with rapid advances and excitement in the field, now is the time combine forces and help accelerate development of ...

A study out of the University of North Carolina at Chapel Hill has unveiled new insights into the inflammatory processes behind periodontitis, a common and debilitating gum disease. Research conducted ...

Neushen Therapeutics Inc. has patented NLRP3 inflammasome inhibitors reported to be useful for the treatment of Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, amyotrophic lateral ...

Every morning of his life, no matter what he did, a young British man woke up with a fever, a headache, a rash on his trunk and limbs, joint pain, and ever-worsening deafness. His doctors had ...

A group of immune proteins called the inflammasome can help prevent blood stem cells from becoming malignant by removing ...

Researchers from Adiso Therapeutics Inc. have reported the discovery of a novel small-molecule dual NLRP1 and NLRP3 inflammasome inhibitor, ADS-032, being developed for the treatment of inflammatory ...